The effect of combining antibiotics on resistance: A systematic review and meta-analysis

Berit Siedentop[1,2*], Viacheslav N. Kachalov[2,3], Christopher Witzany[1], Matthias Egger[4,5,6], Roger D. Kouyos[2,3†], Sebastian Bonhoeffer[1*†]

[1] Institute of Integrative Biology, Department of Environmental Systems Science, ETH Zürich, Zurich, Switzerland

[2] Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland

[3] Institute of Medical Virology, University of Zurich, Zurich, Switzerland

[4] Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

[5] Population Health Sciences, University of Bristol, Bristol, UK

[6] Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

[†]These authors contributed equally

*Berit Siedentop, Sebastian Bonhoeffer

Email: berit.siedentop@env.ethz.ch, seb@env.ethz.ch

Author Contributions: SB, RDK, VNK, and BS conceived and designed the study. RDK and SB supervised the project. BS was responsible for the design of the literature search and the study protocol. VNK, RDK, SB, and ME reviewed the study protocol and approved it. VNK, CW, BS conducted the literature review, performed the data extraction. CW and BS assessed the quality of the studies. RDK, SB and BS conceptualised the statistical analysis. BS analysed the data. BS wrote the initial draft of the manuscript, which was revised by ME, RDK, CW and SB. All authors reviewed and approved the final version of the manuscript.

Competing Interest Statement: We declare no competing interests.

Keywords: antibiotic resistance, resistance evolution, combination therapy, meta-analysis, systematic review

28
Abstract
When and under which conditions antibiotic combination therapy decelerates rather than
accelerates resistance evolution is not well understood. We examined the effect of combining
antibiotics on within-patient resistance development across various bacterial pathogens and
antibiotics.

We searched CENTRAL, EMBASE and PubMed for (quasi)-randomised controlled trials (RCTs)
published from database inception to November 24th, 2022. Trials comparing antibiotic treatments
with different numbers of antibiotics were included. A patient was considered to have acquired
resistance if, at the follow-up culture, a resistant bacterium was detected that had not been
present in the baseline culture. We combined results using a random effects model and
performed meta-regression and stratified analyses. The trials' risk of bias was assessed with the
Cochrane tool.

42 trials were eligible and 29, including 5054 patients, were qualified for statistical analysis. In
most trials, resistance development was not the primary outcome and studies lacked power. The
combined odds ratio (OR) for the acquisition of resistance comparing the group with the higher
number of antibiotics with the comparison group was 1.23 (95% CI 0.68-2.25), with substantial
between-study heterogeneity (I^2 =77%). We identified tentative evidence for potential beneficial or
detrimental effects of antibiotic combination therapy for specific pathogens or medical conditions.

The evidence for combining a higher number of antibiotics compared to fewer from RCTs is
scarce and overall, is compatible with both benefit or harm. Trials powered to detect differences
in resistance development or well-designed observational studies are required to clarify the
impact of combination therapy on resistance.

Significance Statement
52

Antimicrobial resistance is a threat to human health. Antibiotic combinations potentially reduce
resistance. However, conflicting data exists on its effectiveness. To test the effect of antibiotic
combination therapy on resistance, we conducted a meta-analysis of clinical evidence, comparing
higher and lower numbers of antibiotics across various bacterial infections and antibiotic
combinations. We update and expand on previous work that focused on specific infections and
antibiotic combinations. Overall, we found no statistical evidence for a difference in the risk of
resistance acquisition due to lack of power. Thus, despite the increasing threat of antibiotic
resistance, it remains unresolved whether combination therapy de- or accelerates resistance

evolution of bacterial pathogens beyond the well-known conditions where combination therapy is

the standard of care.

Main Text

Introduction

Antibiotics are one of the most significant advances in modern medicine, prescribed to treat

various bacterial infections in both humans and animals and prevent infections, such as surgical

site infections or opportunistic infections in immunocompromised individuals(1). However, this

medical breakthrough is at risk due to the rising prevalence of antibiotic resistance and an

inadequate pipeline of new antibiotics. This disturbing trend threatens to undermine the

effectiveness of antibiotics and poses a severe challenge to public health worldwide.(2, 3) Hence,

we need a more prudent use of antibiotics, and where antibiotics are needed, we need treatment

strategies that reduce the risk that resistance emerges or spreads. Different strategies for the

optimal use of antibiotics have been investigated theoretically and empirically.(4-7) Antibiotic

combination therapy, i.e., the simultaneous administration of several antibiotics, is frequently

discussed as a promising strategy for avoiding resistance evolution.(6-10) It is the standard of

care for some bacterial pathogens, such as *H. pylori*, *Mycobacterium tuberculosis* (Mtb), or

Mycobacterium leprae.(11-13)

There are several motivations for the use of antibiotic combination therapy, including to

broaden the antibiotic spectrum in empirical treatment and reducing antibiotic resistance

development.(14, 15) The simultaneous occurrence of resistance mutations to multiple drugs is

less likely than resistance to single drugs. Combination therapy should, therefore, reduce the

development of resistance.(10) This expectation is supported by viral infections such as HIV,

where multiple point mutations are required for resistance to combination antiviral therapy.

However, it is less clear to what extent this reasoning extends to antibiotic therapy, where the

same mechanism can facilitate bacterial survival against multiple antibiotics,(16, 17) and where

horizontal transfer of resistance may occur. Indeed, the benefit of combining antibiotics for

reducing resistance is debated for bacterial infections.(18) Using more antibiotics overall could

lead to more resistance, as overall antibiotic consumption correlates with resistance.(19)

Two meta-analyses of randomised controlled trials (RCTs) comparing beta-lactam

monotherapy to beta-lactam and aminoglycoside combination therapy found no differences in

resistance development.(4, 5) However, the effect of combining antibiotics on within-patient

resistance development across many bacterial pathogens and antibiotics has not been

addressed. Even though within-patient antibiotic resistance development is rare, it may contribute

to the spread of resistance. We performed a systematic review and meta-analysis to (i) test the

effect of antibiotic combination therapy on within-patient resistance development and (ii) evaluate

which factors affect the performance of combination therapy.

100
101   **Results**
102
The search identified 3082 articles, which decreased to 1837 after deduplication. A total of 488

studies were eligible for full-text review, of which 41 studies qualified for inclusion. The screening

of the citations of the 41 studies identified one additional eligible study, for a total of 42 studies,

40 RCTs and two quasi-RCTs (figure 1, table 1).(20-61) Twenty-nine studies could be included in

the meta-analysis; 13 were excluded due to zero events in both treatment arms.

The included studies were published between 1977 and 2021, with a median publication

year of 1995 and few recent studies (figure 2 A). The development of antibiotic resistance was

typically not the main outcome: only nine studies (21%) explicitly defined a resistance outcome

(SI p 6). Consequently, most studies did not have the statistical power to detect a large effect on

within-patient resistance development (figure 2 B, SI p 14). Twenty-two (52%) focused on a

specific pathogen species (resistant *Acinetobacter baumannii*, *Escherichia coli*, *H. pylori*, Mtb,

methicillin-resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa*, *Staphylococcus*

aureus) or pathogen group (MAC, *Salmonella enterica* subsp. *enterica* serotype Thyphi, or

Salmonella enterica subsp. *enterica* serotype Parthypi A).

The five most frequent reasons for antibiotic administration were treatment or prophylaxis

of urinary tract infections (UTIs) (6 studies, 14%), MRSA (5 studies, 12%), *H.* pylori, MAC, and

prophylaxis for blood cancer patients with four studies (10%) respectively. Twenty-three of the

included studies (55%) compared treatment arms that with at least one administered antibiotic in

common; the remaining studies compared treatment arms with no overlap in administered

antibiotics (table 1). For the outcome acquisition of resistance, only two of all 42 studies had a low

overall risk of bias according to the risk of bias assessment. Twelve (29%) were at high risk of

bias, 28 (67%) at moderate risk of bias (SI p 3).

The overall pooled OR for acquisition of resistance comparing a lower number of

antibiotics versus a higher one was 1.23 (95% CI 0.68 – 2.25), with substantial heterogeneity

between studies (I^2 =77.4%). The latter OR was compatible with the OR for *de novo* emergence

of resistance (pooled OR 0.74, 95% CI 0.34 – 1.59; I^2=77%). Since the results for the two

resistance outcomes are comparable, our focus in the following is on the acquisition of resistance

(details on emergence of resistance can be found in the SI p 2, p 4, p 8).

Stratified analyses revealed that a higher number of antibiotics performed better than a
lower number in case of *H. pylori*, (pooled OR 0.14, 95% CI 0.03 – 0.55; I^2 =41.7%, figure 2A)*,*
and *MAC* (pooled OR 0.18, 95% CI 0.06 – 0.52; I^2 =26.8%, figure 2A)*,* but worse in case of *P.*
aeruginosa (pooled OR 3.42, 95% CI 1.03 – 11.43; I^2=1.54%, figure 2A). Furthermore, a lower
number of antibiotics performed better than a higher number if the compared treatment arms had
no antibiotics in common (pooled OR 4.73, 95% CI 2.14 – 10.42; I^2=37%, SI p 7). In contrast,
when restricting the analysis to studies with at least one common antibiotic in the treatment arms
are pooled there was little evidence of a difference (pooled OR 0.55, 95% CI 0.28 – 1.07; I^2
=74%, figure 3B). When considering only resistance measurements of antibiotics common to both
treatment arms instead of all resistance measurements, the arm with a higher number of
antibiotics shows a benefit in comparison to the one with fewer (pooled OR 0.39, 95% CI 0.18 –
0.81; I^2=75%, SI p 6). If the study measured the acquisition of resistance of both gram negative
and positive bacteria, fewer antibiotics performed better (pooled OR 3.38, 95% CI 1.08 – 10.58;
I^2=38.35%, SI p 5). Other sub-group analyses did not show any harm or benefit of using a higher
number of antibiotics. The results for all subgroup analyses are presented in the supplement (SI p
4). The multi-model inference for our meta-regression showed that the only significant factor
influencing the outcome acquisition of resistance is whether at least one common antibiotic was
used in the comparator arms (for details see SI p 8).

The inspection of the funnel plot and the modified Egger's test showed no indication of a
publication bias (SI p 4). The results were largely robust to the choice of the random effects
model (SI p 8). The probability of the secondary outcome "alterations of the prescribed treatment
due to adverse events", was higher using more antibiotics in comparison to fewer (pooled OR
1.61, 95% CI 1.12 – 2.31; I^2=5%; SI p 10). In 15 studies (36%), the proportion of patients with
alterations of the prescribed treatment due to adverse events was reported, with three studies
(20%) reporting zero cases in both treatment arms. All other analyses of secondary outcomes
showed no indication of harm or benefit of treating with a higher number of antibiotics (SI p 9).

Discussion
158
We performed a meta-analysis of RCTs and quasi-RCTs not limited to a particular
bacterial species, specific condition, or antibiotic combinations to assess the effect of antibiotic
combination therapy on within-patient resistance development. Our analysis could not identify any
benefit or harm of using a higher or a lower number of antibiotics regarding within-patient
resistance development. However, we found some evidence that combining antibiotics may be
beneficial or harmful for specific pathogens or infection types. Acquisition of resistance was rarely
a primary objective of the included RCTs. Hence, they were typically not designed to detect
differences in resistance development between treatment arms and underpowered for this

endpoint. Therefore, the absence of evidence does not mean that there is convincing evidence

for the lack of an effect of using more or fewer antibiotics on resistance development but rather

highlights a knowledge gap. This is remarkable given that the general rise of resistance is an

increasing concern(18, 62) and a priority area for health policy and public health.(63)

Our analysis showed that combining antibiotics reduced resistance development for *H.*

pylori or MAC, in line with the current standard of care.(11, 64) Surprisingly, we found only two

studies that satisfied our inclusion criteria for Mtb(24, 40), which may be considered the prime

example of effective antibiotic combination therapy. The limited number of Mtb studies may be

because antibiotic administration commonly varies during Mtb treatment, which conflicted with our

inclusion criteria that necessitated a consistent treatment regimen for susceptibility

measurements (see SI, page 2). Both eligible Mtb studies were excluded from the analysis due to

the absence of any events in either treatment arm.

Our main result, the absence of a general effect of combining antibiotics on resistance

development, aligns with the two previous meta-analyses.(4, 5) With 42 trials in our systematic

review and 29 in the meta-analysis, our study provided a comprehensive assessment of the effect

of antibiotic combination therapy on within-patient resistance. Whereas previous meta-analyses

focused on a combination of specific antibiotic classes and included fewer than ten studies each,

our study aimed to assess the general effect of combining antibiotics on resistance evolution

across different bacterial pathogens. By including trials with different antibiotic combinations and

bacterial pathogens, we increased clinical and statistical heterogeneity. We accounted for many

sources of heterogeneity using stratification and meta-regression, but analyses were limited by

missing information and sparse data.

Our findings have implications for the design of future studies of resistance development.

Generally, the development of resistance within a patient is a rare event. However, even small

differences could be relevant at the population level. To obtain reliable estimates of such

differences and to better understand the factors influencing them, very large RCTs would be

needed, which systematically investigate the development of antibiotic resistance and include

resistance testing of each administered antibiotic. As such RCTs are costly and associated with

high hurdles, the analysis of cohort studies could be an alternative approach. Over 25 years ago,

Fish et al. published a systematic summary of prospective observational studies reporting data on

resistance development, including antibiotic combination therapy.(65) Similarly, today, relevant

cohort studies could be analysed collaboratively using various modern statistical methods to

address confounding by indication and other biases(66, 67).

The main strength of this study is its comprehensive and systematic approach. For one, it
allowed identifying a knowledge gap regarding the effect of antibiotic combination therapy on
resistance development. Further, our study highlights several issues in the evidence base
evaluating antibiotic combination therapy and resistance development. The included trials did not
always test for susceptibility against all administered antibiotics (table 1). Some antibiotics might
have had reduced potency or were ineffective due to pre-existing resistance mutations.
Furthermore, in studies where treatment was not targeted against a specific pathogen, some
antibiotics may have been inactive against the causative pathogen due to intrinsic resistance.
Indeed, one of the reasons for using combination therapy is to broaden the bacterial spectrum for
empirical therapy(15), which could contribute to an increased risk of antibiotic resistance spread.

Our study had several limitations. First, despite our systematic search, we might have
missed relevant studies. Since resistance development is typically not a primary endpoint and
often not reported systematically, relevant trials are challenging to identify. Our search strategy
aimed to identify a broad range of trials considering resistance development. However, as a
trade-off, our search strategy might have missed trials addressing a specific medical condition or
drug combination. Second, our systematic review and meta-analysis included many older studies
that did not follow the relevant reporting guidelines(68), thereby hampering data extraction and
potentially introducing bias. Third, it is often challenging to discern the specific mechanisms by
which resistance develops based on the data from clinical trials. This includes distinguishing
whether resistance arises *de novo*, if the pathogen acquires resistance through horizontal gene
transfer, if the patient becomes newly infected with a resistant pathogen, or if the pathogen was
present but undetected at the beginning of treatment. These scenarios can impact the
effectiveness of combination therapy. For example, combination therapy may be more likely to
select any pre-existing resistant pathogens compared to monotherapy due to the use of multiple
antibiotics. We addressed some of this heterogeneity by employing two different measures of
resistance (see SI, page 2). Furthermore, the variation in standards that classify bacteria as
susceptible or resistant adds another layer of heterogeneity alongside the technical limitations in
detecting resistance development.

In conclusion, combination therapy offers potential advantages and disadvantages
regarding resistance evolution and spread. On the one hand, combination therapy typically
increases the genetic barrier to resistance, and it has become the standard therapy for pathogens
notorious for resistance evolution. Therefore, combination therapy remains a plausible candidate
strategy to slow down resistance evolution. On the other hand, combination therapy generates
selection pressure for resistance to multiple antibiotics simultaneously and could, therefore,
accelerate resistance evolution – especially in the microbiome. Given the critical nature of this

context, it is profoundly disconcerting that there is a lack of evidence elucidating the impact of

combining antibiotics on the development of resistance

Materials and Methods

238
Inclusion criteria and search strategy

We did a systematic review and meta-analysis to summarise the evidence on the effect of

antibiotic combination therapy on resistance development. We included RCTs and quasi-RCTs

comparing treatments with a higher number of antibiotics to treatments with a lower number of

antibiotics. Studies were classified as quasi-RCTs if the allocation of participants to study arms

was not truly random. We did not consider antiseptics or compounds supporting the activity of

antibiotics, such as beta-lactam inhibitors as antibiotics itself. Whereas the antibiotic substances

administered within one treatment arm had to be the same for all patients, the antibiotics could

differ between treatment arms. We required baseline and follow-up cultures with resistance

measurements to determine the treatment impact on resistance. We considered only antibiotic

treatment regimens fixed for the period between two resistance measurements. Hence, we

excluded sequential and cycling regimens.

We searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials

(CENTRAL) from inception up to 24.11.2022, using keywords, medical subject headings (MeSH),

and EMTREE terms related to bacterial infection, antibiotics, combination therapy, resistance and

RCTs. We excluded complementary and alternative medicine and bismuth. The search strategy

is detailed in the SI (p 26). After a systematic deduplication process,(69) VNK (or CW) and BS

independently screened the titles and abstracts, and, if potentially eligible, the full texts. Any

discrepancies between VNK (or CW) and BS were discussed and resolved. At full-text screening,

we excluded articles that were not accessible in English or German. We screened the references

of eligible studies and the trials included in two previous meta-analyses.(4, 5) We followed the

PRISMA reporting guidelines(70) and registered our protocol with PROSPERO

(CRD42020187257).

Outcomes

We used two definitions for the primary outcome resistance. A broader definition, "acquisition of

resistance", and a stricter "*de novo* emergence of resistance" definition, where the latter is a

subset of the former. A patient was considered to have acquired resistance if, at the follow-up

culture a resistant bacterium was detected that was not present in the baseline culture. *De novo*

emergence of resistance was defined as the detection of a resistant bacterium that was present

at baseline but sensitive. Additional secondary outcomes included mortality from all causes and

infection, treatment failure overall, treatment failure due to resistance, treatment change due to

adverse effects, and acquisition/*de novo* emergence of resistance against non-administered

antibiotics. The SI (p 2, p 18) provides further details.

Data extraction and analysis

VNK (or CW) and BS independently extracted all study data using a standardised form (see

https://osf.io/gwefy/?view_only=f6a4c1f4c79241038b203bd03c8e1845). The data extracted

included the proportion of patients who developed the two primary outcomes and the secondary

outcomes and study characteristics such as type of trial (RCT or quasi-RCT), follow-up and

treatment duration, number of antibiotics in the treatment arms, type of antibiotic, and presence of

comorbidities. Any discrepancies in data extraction were discussed and resolved.

We calculated odds ratios (ORs) with 95% confidence intervals (CIs), comparing a higher

with a lower number of antibiotics for each study. We combined ORs using a modified version of

the Simmonds and Higgins random effects model.[71] If a study had more than two eligible

treatment arms, they were merged for statistical analysis. Studies with zero events in both

treatment arms were excluded from the statistical analysis. We used subgroup analyses and

meta-regressions with multi-model inference to examine the influence of pre-specified variables

on summary ORs. Variables included whether the antibiotic(s) used in the arm with the lower

number of antibiotics are also part of the arm(s) with the higher number of antibiotics, the number

of antibiotics administered, the age of the antibiotics (time since market entry), the administration

of other non-antibiotic drugs, whether participants had specific comorbidities or were in intensive

care, gram-status of the tested pathogens, and the length of antibiotic treatment and follow-up.

We extended our predefined analysis regarding the reason for antibiotic treatment/type of

pathogen, which was initially restricted to only *H. pylori* and Mtb, as we found enough studies to

stratify by other conditions/pathogens. We furthermore performed post-hoc subgroup analyses to

examine the following factors: treatment of resistant pathogens, additional antibiotic

administration besides the fixed treatment, and the way of antibiotic administration (SI p 14).

Between study heterogeneity was estimated with I^2, using the criteria for I^2 specified in

Higgins et al. for classifying the degree of heterogeneity.[72] CW and BS assessed each study's

quality for the main outcomes using the Risk of Bias tool (RoB 2, SI p 7).[73] To assess

publication bias, we visually inspected the funnel plot and a modified Egger's test (SI p 10). We

performed sensitivity analyses on the model choice (SI p 8), and risk of bias (SI p 9), and

performed a post-hoc trial sequential analysis (SI p 17). Statistical analyses and visualisations

were done in R (version 4.2.1) using packages *metafor* and *MuMIn*.[74, 75]

Acknowledgments

Support from the Swiss National Science Foundation (grant 310030B_176401 (SB, BS, CW), grant 32FP30-174281 (ME), grant 324730_207957 (RDK)) and from the National Institute of Allergy and Infectious Diseases (NIAID, cooperative agreement AI069924 (ME)) is gratefully acknowledged. We thank Anthony Hauser, João Pires and Frédérique Lachmann for helpful discussions and Annelies Zinkernagel and Johannes Nemeth for critical reading of the manuscript. Furthermore, we are grateful for all contacted study authors that responded to our inquiries and provided further information.

References

1. R. A. Taplitz *et al.*, Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. *Journal of Clinical Oncology* **36**, 3043-3054 (2018).

2. M. I. Hutchings, A. W. Truman, B. Wilkinson, Antibiotics: past, present and future. *Current Opinion in Microbiology* **51**, 72-80 (2019).

3. C. J. L. Murray *et al.*, Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* **399**, 629-655 (2022).

4. I. A. Bliziotis, G. Samonis, K. Z. Vardakas, S. Chrysanthopoulou, M. E. Falagas, Effect of Aminoglycoside and β-Lactam Combination Therapy versus β-Lactam Monotherapy on the Emergence of Antimicrobial Resistance: A Meta-analysis of Randomized, Controlled Trials. *Clinical Infectious Diseases* **41**, 149-158 (2005).

5. M. Paul, A. Lador, S. Grozinsky-Glasberg, L. Leibovici, Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. *Cochrane Database of Systematic Reviews* 10.1002/14651858.CD003344.pub3 (2014).

6. D. C. Angst, B. Tepekule, L. Sun, B. Bogos, S. Bonhoeffer, Comparing treatment strategies to reduce antibiotic resistance in an in vitro epidemiological setting. *Proceedings of the National Academy of Sciences* **118**, e2023467118 (2021).

7. B. Tepekule, H. Uecker, I. Derungs, A. Frenoy, S. Bonhoeffer, Modeling antibiotic treatment in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies. *PLOS Computational Biology* **13**, e1005745 (2017).

8. G. J. Sullivan, N. N. Delgado, R. Maharjan, A. K. Cain, How antibiotics work together: molecular mechanisms behind combination therapy. *Current Opinion in Microbiology* **57**, 31-40 (2020).

9. M. Tyers, G. D. Wright, Drug combinations: a strategy to extend the life of antibiotics in the 21st century. *Nature Reviews Microbiology* **17**, 141-155 (2019).

10. S. Bonhoeffer, M. Lipsitch, B. R. Levin, Evaluating treatment protocols to prevent antibiotic resistance. *Proceedings of the National Academy of Sciences* **94**, 12106-12111 (1997).

11. V. De Francesco, A. Bellesia, L. Ridola, R. Manta, A. Zullo, First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. *Ann Gastroenterol* **30**, 373-379 (2017).

12. R. Singh *et al.*, Recent updates on drug resistance in Mycobacterium tuberculosis. *Journal of Applied Microbiology* **128**, 1547-1567 (2020).

13.   W. Alemu Belachew, B. Naafs, Position statement: LEPROSY: Diagnosis, treatment and
follow-up. *Journal of the European Academy of Dermatology and Venereology* **33**, 1205-
1213 (2019).
14.   M. W. Pletz, S. Hagel, C. Forstner, Who benefits from antimicrobial combination
therapy? *The Lancet Infectious Diseases* **17**, 677-678 (2017).
15.   R. Roemhild, T. Bollenbach, D. I. Andersson, The physiology and genetics of bacterial
responses to antibiotic combinations. *Nature Reviews Microbiology* 10.1038/s41579-
022-00700-5 (2022).
16.   D. Du *et al.*, Multidrug efflux pumps: structure, function and regulation. *Nature Reviews*
Microbiology **16**, 523-539 (2018).
17.   V. Lázár, O. Snitser, D. Barkan, R. Kishony, Antibiotic combinations reduce
Staphylococcus aureus clearance. *Nature* **610**, 540-546 (2022).
18.   A. H. Holmes *et al.*, Understanding the mechanisms and drivers of antimicrobial
resistance. *The Lancet* **387**, 176-187 (2016).
19.   H. Goossens, M. Ferech, R. Vander Stichele, M. Elseviers, Outpatient antibiotic use in
Europe and association with resistance: a cross-national database study. *The Lancet* **365**,
579-587 (2005).
20.   J. F. Bender *et al.*, Role of vancomycin as a component of oral nonabsorbable antibiotics
for microbial suppression in leukemic patients. *Antimicrobial agents and chemotherapy*
15, 455-460 (1979).
21.   R. E. Black, M. M. Levine, M. L. Clements, L. Cisneros, V. Daya, Treatment of
experimentally induced enterotoxigenic Escherichia coli diarrhea with trimethoprim,
trimethoprim-sulfamethoxazole, or placebo. *Reviews of infectious diseases* **4**, 540-545
(1982).
22.   R. E. Chaisson *et al.*, Clarithromycin and ethambutol with or without clofazimine for the
treatment of bacteremic Mycobacterium avium complex disease in patients with HIV
infection. *AIDS (London, England)* **11**, 311-317 (1997).
23.   A. Cometta *et al.*, Prospective randomized comparison of imipenem monotherapy with
imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.
Antimicrobial agents and chemotherapy **38**, 1309-1313 (1994).
24.   R. Dawson *et al.*, Efficiency and safety of the combination of moxifloxacin, pretomanid
(PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a
phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-
resistant pulmonary tuberculosis. *Lancet (london, england)* **385**, 1738-1747 (2015).
25.   A. W. Dekker, M. Rozenberg-Arska, J. Verhoef, Infection prophylaxis in acute leukemia: a
comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. *Annals of*
internal medicine **106**, 7-11 (1987).
26.   Y. Dickstein *et al.*, Colistin Resistance Development Following Colistin-Meropenem
Combination Therapy vs. Colistin Monotherapy in Patients with Infections Caused by
Carbapenem-Resistant Organisms. *Clinical infectious diseases : an official publication of*
the Infectious Diseases Society of America 10.1093/cid/ciz1146 (2019).
27.   M. P. Dubé *et al.*, A randomized evaluation of ethambutol for prevention of relapse and
drug resistance during treatment of Mycobacterium avium complex bacteremia with
clarithromycin-based combination therapy. *Journal of Infectious Diseases* **176**, 1225-
1232 (1997).

28. E. Durante-Mangoni *et al.*, Colistin and rifampicin compared with colistin alone for the
treatment of serious infections due to extensively drug-resistant Acinetobacter
baumannii: a multicenter, randomized clinical trial. *Clinical infectious diseases* **57**, 349-
358 (2013).
29. S. Fournier *et al.*, Effect of adding clofazimine to combined clarithromycin-ethambutol
therapy for Mycobacterium avium complex septicemia in AIDS patients. *European*
journal of clinical microbiology & infectious diseases **18**, 16-22 (1999).
30. W. B. Gerecht *et al.*, Prospective randomized comparison of mezlocillin therapy alone
with combined ampicillin and gentamicin therapy for patients with cholangitis. *Archives*
of internal medicine **149**, 1279-1284 (1989).
31. J. Gibson *et al.*, A randomised trial of empirical antibiotic therapy in febrile neutropenic
patients with hematological disorders: ceftazidime versus azlocillin plus amikacin.
Australian and New Zealand journal of medicine **19**, 417-425 (1989).
32. D. A. Haase *et al.*, Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole
in the treatment of women with localized, acute, symptomatic urinary tract infections
and antimicrobial effect on periurethral and fecal microflora. *Antimicrobial agents and*
chemotherapy **26**, 481-484 (1984).
33. S. Harbarth *et al.*, Randomized non-inferiority trial to compare
trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of
MRSA infection. *Journal of antimicrobial chemotherapy* **70**, 264-272 (2015).
34. M. E. Hodson, C. M. Roberts, R. J. Butland, M. J. Smith, J. C. Batten, Oral ciprofloxacin
compared with conventional intravenous treatment for Pseudomonas aeruginosa
infection in adults with cystic fibrosis. *Lancet (london, england)* **1**, 235-237 (1987).
35. I. M. Hoepelman, M. Rozenberg-Arska, J. Verhoef, Comparative study of ceftriaxone
monotherapy versus a combination regimen of cefuroxime plus gentamicin for
treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora.
Chemotherapy **34 Suppl 1**, 21-29 (1988).
36. K. Hultén, B. Jaup, B. Stenquist, L. Engstrand, Combination treatment with ranitidine is
highly efficient against Helicobacter pylori despite negative impact of macrolide
resistance. *Helicobacter* **2**, 188-193 (1997).
37. A. Iravani, G. A. Richard, H. Baer, R. Fennell, Comparative efficacy and safety of nalidixic
acid versus trimethoprim/sulfamethoxazole in treatment of acute urinary tract
infections in college-age women. *Antimicrobial agents and chemotherapy* **19**, 598-604
(1981).
38. R. F. Jacobs *et al.*, Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic
children. *Infection* **21**, 223-228 (1993).
39. J. H. Jo *et al.*, Alterations of human skin microbiome and expansion of antimicrobial
resistance after systemic antibiotics. *Sci Transl Med* **13**, eabd8077 (2021).
40. M. F. Macnab, P. D. Bohmer, J. R. Seager, Evaluation of the 3-drug combination, Rifater,
versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. *South*
African medical journal **84**, 325-328 (1994).
41. N. Markowitz, E. L. Quinn, L. D. Saravolatz, Trimethoprim-sulfamethoxazole compared
with vancomycin for the treatment of Staphylococcus aureus infection. *Annals of*
internal medicine **117**, 390-398 (1992).
42. E. Mavromanolakis, S. Maraki, G. Samonis, Y. Tselentis, A. Cranidis, Effect of norfloxacin,
trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with

recurrent urinary tract infections. *Journal of chemotherapy (Florence, Italy)* **9**, 203-207
(1997).
43.   T. May *et al.*, Comparison of combination therapy regimens for treatment of human
immunodeficiency virus-infected patients with disseminated bacteremia due to
Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche
sur le Sida. *Clinical infectious diseases* **25**, 621-629 (1997).
44.   J. M. McCarty *et al.*, Comparison of piperacillin alone versus piperacillin plus tobramycin
for treatment of respiratory infections in children with cystic fibrosis. *Pediatric*
pulmonology **4**, 201-204 (1988).
45.   R. Menon *et al.*, Comparison of a slow-release trimethoprim with co-trimoxazole:
efficacy and selection of resistance in the Enterobacteriaceae. *Journal of antimicrobial*
chemotherapy **18**, 415-420 (1986).
46.   S. Miehlke *et al.*, Comparison of omeprazole, metronidazole and clarithromycin with
omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection.
Digestion **59**, 646-650 (1998).
47.   F. Parras *et al.*, Comparative study of mupirocin and oral co-trimoxazole plus topical
fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus
aureus. *Antimicrobial agents and chemotherapy* **39**, 175-179 (1995).
48.   M. F. Parry *et al.*, Treatment of pulmonary infections in patients with cystic fibrosis: a
comparative study of ticarcillin and gentamicin. *J Pediatr* **90**, 144-148 (1977).
49.   C. M. Parry *et al.*, Randomized controlled comparison of ofloxacin, azithromycin, and an
ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic
acid-resistant typhoid fever. *Antimicrobial agents and chemotherapy* **51**, 819-825
(2007).
50.   M. Paul *et al.*, Trimethoprim-sulfamethoxazole versus vancomycin for severe infections
caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. *BMJ*
(Clinical research ed.) **350**, h2219 (2015).
51.   J. M. Pogue *et al.*, Emergence of Colistin Resistance in the OVERCOME Trial: Impact of
Combination Therapy with Meropenem. *Open Forum Infectious Diseases* **8**, S418-S419
(2021).
52.   M. Pujol *et al.*, Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-
resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical
Trial. *Clin Infect Dis* **72**, 1517-1525 (2021).
53.   E. Rubinstein *et al.*, Ceftazidime monotherapy vs. Ceftriaxone/tobramycin for serious
hospital- acquired gram-negative infections. *Clinical Infectious Diseases* **20**, 1217-1228
(1995).
54.   A. J. Schaeffer, S. Flynn, J. Jones, Comparison of cinoxacin and trimethoprim-
sulfamethoxazole in the treatment of urinary tract infections. *Journal of urology* **125**,
825-827 (1981).
55.   A. J. Schaeffer, G. A. Sisney, Efficacy of norfloxacin in urinary tract infection biological
effects on vaginal and fecal flora. *Journal of urology* **133**, 628-630 (1985).
56.   A. L. Smith *et al.*, Comparison of a β-lactam alone versus β-lactam and an
aminoglycoside for pulmonary exacerbation in cystic fibrosis. *Journal of Pediatrics* **134**,
413-421 (1999).
57.   W. A. Stack *et al.*, Safety and efficacy of rabeprazole in combination with four antibiotic
regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with

or without peptic ulceration. *American journal of gastroenterology* **93**, 1909-1913
(1998).
58.   T. J. Walsh *et al.*, Randomized double-blinded trial of rifampin with either novobiocin or
trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus
colonization: prevention of antimicrobial resistance and effect of host factors on
outcome. *Antimicrobial agents and chemotherapy* **37**, 1334-1342 (1993).
59.   D. J. Winston, W. G. Ho, S. L. Nakao, R. P. Gale, R. E. Champlin, Norfloxacin versus
vancomycin/polymyxin for prevention of infections in granulocytopenic patients. *Am J*
Med **80**, 884-890 (1986).
60.   D. J. Winston, W. G. Ho, D. A. Bruckner, R. P. Gale, R. E. Champlin, Ofloxacin versus
vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
American journal of medicine **88**, 36-42 (1990).
61.   H. Wurzer *et al.*, Short-course therapy with amoxycillin-clarithromycin triple therapy for
10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study
Group. *Alimentary pharmacology & therapeutics* **11**, 943-952 (1997).
62.   C. J. L. Murray *et al.*, Global burden of bacterial antimicrobial resistance in 2019: a
systematic analysis. *The Lancet* 10.1016/S0140-6736(21)02724-0.
63.   L. T. Joshi, The G7 Summit 2021: time for our world leaders to step up to the challenge
of antimicrobial resistance. *Access Microbiology* **3** (2021).
64.   A. Kerantzas Christopher, R. Jacobs William, J. Rubin Eric, R. J. Collier, Origins of
Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development
and Application. *mBio* **8**, e01586-01516.
65.   D. N. Fish, S. C. Piscitelli, L. H. Danziger, Development of resistance during antimicrobial
therapy: a review of antibiotic classes and patient characteristics in 173 studies.
Pharmacotherapy **15**, 279-291 (1995).
66.   M. A. Hernán, W. Wang, D. E. Leaf, Target Trial Emulation: A Framework for Causal
Inference From Observational Data. *JAMA* **328**, 2446-2447 (2022).
67.   M. A. Hernán, Methods of Public Health Research — Strengthening Causal Inference
from Observational Data. *New England Journal of Medicine* **385**, 1345-1348 (2021).
68.   K. F. Schulz, D. G. Altman, D. Moher, C. G. for the, CONSORT 2010 Statement: Updated
Guidelines for Reporting Parallel Group Randomised Trials. *PLOS Medicine* **7**, e1000251
(2010).
69.   W. M. Bramer, D. Giustini, G. B. de Jonge, L. Holland, T. Bekhuis, De-duplication of
database search results for systematic reviews in EndNote. *J Med Libr Assoc* **104**, 240-
243 (2016).
70.   M. J. Page *et al.*, The PRISMA 2020 statement: an updated guideline for reporting
systematic reviews. *Systematic Reviews* **10**, 89 (2021).
71.   D. Jackson, M. Law, T. Stijnen, W. Viechtbauer, I. R. White, A comparison of seven
random-effects models for meta-analyses that estimate the summary odds ratio. *Stat*
Med **37**, 1059-1085 (2018).
72.   J. J. Deeks, J. P. T. Higgins, D. G. Altman, "Analysing Data and Undertaking Meta-
Analyses". (John Wiley & Sons, Ltd, Chichester, UK, 2008), 10.1002/9780470712184.ch9,
pp. 243-296.
73.   J. A. C. Sterne *et al.*, RoB 2: a revised tool for assessing risk of bias in randomised trials.
BMJ **366**, l4898 (2019).

74.   W. Viechtbauer, Conducting Meta-Analyses in R with the metafor Package. *Journal of*
Statistical Software **36**, 1 - 48 (2010).
75.   K. Bartoń (2020) MuMIn: Multi-Model Inference.

Figures and Tables

Figure 1. Study selection

Figure 2. Measuring antibiotic resistance is not a current main objective of RCTs. A) Distribution of the publishing year of included studies, where n indicates the number of studies, and the red vertical line the median of the distribution. B) Calculated power of included studies to detect an odds ratio of 0.5. The power calculations were based on equal treatment arm sizes. For the calculations the treatment arm with the higher number of patients of the respective studies was used.

Figure 3. Forest plot of acquisition of bacterial resistance stratified by the reason antibiotics were administered. The coloring indicates the number of antibiotics that were compared in each study. A) The overall pooled LOR of all included studies. B) The pooled LOR of studies with at least one antibiotic in common in the treatment arms. UTI stands for urinary tract infection, MRSA for methicillin-resistant Staphylococcus aureus, MAC for Mycobacterium avium complex, and BSI for blood stream infection.

Table 1. Overview of the 42 RCTs or quasi-RCTs included in the systematic review and meta-analysis. The underlined antibiotics indicate that resistance measurements were made for this antibiotic, reported and extractable from the studies. Resistance outcome definitions marked with (*) indicate that the definition was not specifically provided by the study itself but states our justification for extraction.

STUDY	TYPE OF STUDY	FOCUSED PATHOGEN/ REASON FOR ANTIBIOTIC TREATMENT	OBJECTIVE(S)	ANTIBIOTICS USED IN STUDY ARMS		EXPLICIT DEFINITION OF RESISTANCE OUTCOME	SECONDARY OUTCOMES EXTRACTED
				LESS ANTIBIOTICS	MORE ANTIBIOTICS		
Bender et al. (1979)(20)	RCT	Infection prophylaxis for patients with acute leukemia or malignant lymphomas receiving remission induction chemotherapy	Tolerance, suppression of microbial flora, protection against colonisation and infection	Gentamicin	Gentamicin, and vancomycin	no	All-cause mortality
Black et al. (1982)(21)	RCT	enterotoxigenic *Escherichia coli* (ETEC)	Compare two treatments options against ECET.	Trimethoprim	Trimethoprim, and sulfamethoxazole	no	-
Chaisson et al. (1997)(22)	RCT	MAC	Safety and activity	Clarithromycin, and ethambutol	Clarithromycin, ethambutol, and clofazimine	no	All-cause mortality

Cometta et al. (1997)(23)	RCT	Nosocomial pneumonia, nosocomial sepsis, or severe diffuse peritonitis	Clinical efficacy and tolerance, emergence of resistance and risk of superinfection	Imipenem	Imipenem, and netilmicin	no	Mortality attributable to infection, treatment failure, treatment failure due to a change of resistance against the study drugs
Dawson et al. (2015)(24)	RCT	Mtb	Efficacy, and safety	Moxifloxacin, pretomanid, and pyrazinamide	Isoniazid, rifampicin, pyrazinamide, and ethambutol	no	Proportion of patients with alterations of the prescribed treatment due to adverse events
Dekker et al. (1987)(25)	RCT	Prophylaxis for acute nonlymphocytic or lymphocytic leukemia	Efficacy of protecting against infections	Ciprofloxacin	Trimethoprim, and sulfamethoxazole	no	All-cause mortality, mortality attributable to infection, acquisition of resistance against non-administered antibiotics
Dickstein et al. (2019)(26)	RCT	Carbapenem resistant, colistin-susceptible, and gram-negative infections	Development of colistin resistance (secondary outcome of a clinical trial)	Colistin	Colistin, and meropenem	yes	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Dubé et al. (1997)(27)	RCT	MAC	Risk of recrudescent MAC bacteraemia, emergence of resistance to clarithromycin.	Clarithromycin, and clofazimine	Clarithromycin, clofazimine, and ethambutol	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Durante-Mangoni et al. (2013)(28)	RCT	Extensively drug resistant *Acinetobacter baumannii*	Mortality	Colistin	Colistin, and rifampicin	yes	All-cause mortality, mortality attributable to infection, treatment failure
Fournier et al. (1999)(29)	RCT	MAC	Efficacy and tolerance.	Clarithromycin, ethambutol	Clarithromycin, ethambutol, and clofazimine	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events

Gerecht et al. (1989)(30)	RCT	Cholangitis	Compare a single drug treatment to a two-drug treatment.	Mezlocillin	Ampicillin, and gentamicin	yes	All-cause mortality, treatment failure as reported in each study, treatment failure due to a change of resistance against the study drugs
Gibson et al. (1989)(31)	RCT	Febrile neutropenia	Efficacy and side effects	Ceftazidime	Azlocillin, and amikacin	no	All-cause mortality, mortality attributable to infection, proportion of patients with alterations of the prescribed treatment due to adverse events, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Haase et al. (1984)(32)	RCT	UTI	Efficacy, tolerance, and safety	Norfloxacin	Trimethoprim, and sulfamethoxazole	no	Treatment failure, acquisition of resistance against non-administered antibiotics
Hartbarth et al. (2015)(33)	RCT	MRSA	Assess the non-inferiority of a multiple drug treatment in comparison of a single drug treatment.	Linezolid	Trimethoprim, sulfamethoxazole, and rifampicin	no	All-cause mortality, mortality attributable to infection, treatment failure
Hodson (1987)(34)	RCT	Cystic fibrosis patients with *P. aeruginosa*	Compare an oral one drug treatment to an intravenous two drug treatment.	Ciprofloxacin	Azlocillin, and gentamicin	no	-
Hoepelman et al. (1988)(35)	RCT	Serious bacterial infections	Emergence of resistance of fecal flora	Ceftriaxone	Cefuroxime, and gentamicin	no	Proportion of patients with alterations of the prescribed treatment due to adverse events
Hultén et al. (1997)(36)	RCT	*H. pylori*	Antibacterial efficacy, emergence of clarithromycin resistance.	Clarithromycin	Clarithromycin, and lymecycline	no	-
Iravani et al. (1981)(37)	RCT	Acute UTI	Efficacy, treatment effects on fecal flora, resistance emergence in the infecting pathogen	Nalidixic acid	Trimethoprim, and sulfamethoxazole	no	-

Jacobs et al. (1993)(38)	RCT	Bacterial infections in neutropenic children	Efficacy and safety, tolerance, emergence of resistance and risk of superinfection	Ceftazidime	Ceftazidime, and tobramycin	yes	All-cause mortality, treatment failure, treatment failure due to a change of resistance against the study drugs
Jo et al. (2021)(39)	RCT	Determine impact of antibiotics on healthy skin microbiota	Investigate short and long term of the skin microbiome	Doxycycline	Trimethoprim, and sulfamethoxazole	no	-
Macnab et al. (1994)(40)	Quasi-RCT	Mtb	Efficacy, primary drug resistance, bacteriological conversion rates, compliance, and side effects	Isoniazid, and rifampicin	Isoniazid, rifampicin, and ethambutol	no	Proportion of patients with alterations of the prescribed treatment due to adverse event
Markowitz et al. (1992)(41)	RCT	*S. aureus*	Efficacy and safety	Vancomycin	Trimethoprim, and sulfamethoxazole	no	All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Mavromanolakis et al. (1997)(42)	RCT	Recurrent UTIs	Effect on the aerobic bowel flora, frequency of resistant strains in the fecal flora during and after treatment.	Norfloxacin, or Nitrofurantoin	Trimethoprim, and sulfamethoxazole	no	-
May et al. (1997)(43)	RCT	MAC	Clinical and bacteriological efficacy, safety, tolerability	Clarithromycin, and clofazimine	Clarithromycin, rifabutin, and ethambutol	no	All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Mc Carty et al. (1988)(44)	RCT	Cystic fibrosis patients with *P. aeruginosa*	Safety, pharmacokinetics of a high-dose singe drug treatment, the effectiveness	Piperacillin	Piperacillin, and tobramycin	no	All-cause mortality, mortality attributable to infection
Menon et al. (1986)(45)	RCT	Acute UTI	Efficacy, selection of resistance in Enterobacteriaceae	Trimethoprim	Trimethoprim, and sulfamethoxazole	no	Acquisition of resistance against non-administered antibiotics

Miehlke et al. (1998)(46)	RCT	*H. pylori*	Effectiveness, tolerability	Amoxicillin	Clarithromycin, and metronidazole	no	Proportion of patients with alterations of the prescribed treatment due to adverse events
Parras et al. (1995)(47)	RCT	MRSA	Efficacy to eradicate, safety	Mupirocin	Sodium fusidate, trimethoprim, and sulfamethoxazole	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Parry et al. (1977)(48)	Quasi-RCT	*Pulmonary infection*	Effectiveness, treatment failure, treatment success, frequency of ticarcillin resistant organisms, influence of resistance on disease development	Ticarcillin	Ticarcillin, and gentamicin	no	-
Parry et al. (2007)(49)	RCT	Multidrug resistant typhoid fever	Efficacy	Ofloxacin, or Azithromycin	Ofloxacin, and Azithromycin	no	Treatment failure
Paul et al. (2015)(50)	RCT	MRSA	Test whether a two-drug treatment is non-inferior to a two-drug treatment.	Vancomycin	Trimethoprim, and sulfamethoxazole	yes	All-cause mortality, treatment failure, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Pogue et al. (2021)(51)	RCT	Gram negative resistant bloodstream infections or pneumonia	Assess superiority of a combination of colistin to monotherapy.	Colistin	Colistin, and meropenem	yes	All-cause mortality, treatment failure
Pujol et al. (2021)(52)	RCT	MRSA	Assess treatment success.	Daptomycin	Daptomycin, and fosfomycin		All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Rubinstein et al. (1995)(53)	RCT	Gram-negative hospital acquired infections	Efficacy, safety	Ceftazidime	Ceftriaxone, and Tobramycin	yes	All-cause mortality, mortality attributable to infection, treatment failure, proportion of patients with

							alterations of the prescribed treatment due to adverse events
Schaeffer et al. (1981)(54)	RCT	UTI	Effectiveness, safety, incidence of resistance in faecal and vaginal flora before, and after treatment.	Cinoxacin	Trimethoprim, and sulfamethoxazole	no	Proportion of patients with alterations of the prescribed treatment due to adverse events
Schaeffer et al. (1985)(55)	RCT	UTI	Effectiveness, safety, incidence of resistance in fecal and vaginal flora before, and after treatment.	Norfloxacin	Trimethoprim, and sulfamethoxazole	no	-
Smith et al. (1999)(56)	RCT	P. aeruginosa	Efficacy	Azlocillin	Azlocillin, and tobramycin	no	Acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Stack et al. (1998)(57)	RCT	*H. pylori*	Efficacy, safety	Clarithromycin	Clarithromycin, and metronidazole, or amoxycillin	no	-
Walsh et al. (1993)(58)	RCT	MRSA	Efficacy of eradication, emergence of resistance, safety	Novobiocin, and rifampicin	Rifampicin, trimethoprim, and sulfamethoxazole	yes	Treatment failure, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Winston et al. (1986)(59)	RCT	Prophylaxis for blood cancer patients	Efficacy and safety	Norfloxacin	Vancomycin, and polymyxin	no	Mortality attributable to infection
Winston et al. (1990)(60)	RCT	Prophylaxis for blood cancer patients	Efficacy and safety	Ofloxacin	Vancomycin, and polymyxin	no	-
Wurzer et al. (1997)(61)	RCT	*H. pylori*	Effectiveness, emergence of resistance.	Clarithromycin	Clarithromycin, and amoxycillin	no	-